Precision Medicine for Continuing Phenotype Expansion of Human Genetic Diseases

Determining the exact genetic causes for a patient and providing definite molecular diagnoses are core elements of precision medicine. Individualized patient care is often limited by our current knowledge of disease etiologies and commonly used phenotypic-based diagnostic approach. The broad and incompletely understood phenotypic spectrum of a disease and various underlying genetic heterogeneity also present extra challenges to our clinical practice. With the rapid adaptation of new sequence technology in clinical setting for diagnostic purpose, phenotypic expansions of disease spectrum are becoming increasingly common. Understanding the underlying molecular mechanisms will help us to integrate genomic information into the workup of individualized patient care and make better clinical decisions.

[1]  W. Marsden.  I and J , 2012 .

[2]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[3]  Dan M. Roden,et al.  Implementing genomic medicine in the clinic: the future is here , 2013, Genetics in Medicine.

[4]  Kelly Schoch,et al.  Clinical application of exome sequencing in undiagnosed genetic conditions , 2012, Journal of Medical Genetics.

[5]  Vineet Bafna,et al.  Exome Sequencing Can Improve Diagnosis and Alter Patient Management , 2012, Science Translational Medicine.

[6]  Philippe Bédard,et al.  Clinical application of high-throughput genomic technologies for treatment selection in breast cancer , 2013, Breast Cancer Research.

[7]  F. Glorieux,et al.  Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans , 2007, Human mutation.

[8]  P. Beales,et al.  Ciliopathies: an expanding disease spectrum , 2011, Pediatric Nephrology.

[9]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[10]  W. Craigen,et al.  Mitochondrial DNA polymerase γ mutations: an ever expanding molecular and clinical spectrum , 2011, Journal of Medical Genetics.

[11]  R. Wilson,et al.  The Next-Generation Sequencing Revolution and Its Impact on Genomics , 2013, Cell.

[12]  Avi Ma'ayan,et al.  Identification of small exonic CNV from whole-exome sequence data and application to autism spectrum disorder. , 2013, American journal of human genetics.

[13]  Damian Smedley,et al.  The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data , 2014, Nucleic Acids Res..

[14]  J. Schiffman,et al.  Translating genomic discoveries to the clinic in pediatric oncology , 2015, Current opinion in pediatrics.

[15]  Bethan E. Hoskins,et al.  Heterozygous mutations in BBS1, BBS2 and BBS6 have a potential epistatic effect on Bardet-Biedl patients with two mutations at a second BBS locus. , 2003, Human molecular genetics.

[16]  L. Moens,et al.  Diagnostics of Primary Immunodeficiency Diseases: A Sequencing Capture Approach , 2014, PloS one.

[17]  Nikhil Wagle,et al.  High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.

[18]  Marni J. Falk,et al.  Practice patterns of mitochondrial disease physicians in North America. Part 1: diagnostic and clinical challenges. , 2014, Mitochondrion.

[19]  David W. Evans,et al.  Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence , 2013, The Lancet Neurology.

[20]  J. Lupski,et al.  TBX6 null variants and a common hypomorphic allele in congenital scoliosis. , 2015, The New England journal of medicine.

[21]  Amna Z. Shah,et al.  Dominant PRPF31 Mutations Are Hypostatic to a Recessive CNOT3 Polymorphism in Retinitis Pigmentosa: A Novel Phenomenon of “Linked Trans-Acting Epistasis” , 2013, Annals of human genetics.

[22]  Steven J. M. Jones,et al.  FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project. , 2014, American journal of human genetics.

[23]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[24]  Heidi L Rehm,et al.  New approaches to molecular diagnosis. , 2013, JAMA.

[25]  Todd Richmond,et al.  Detection of Clinically Relevant Copy Number Variants with Whole‐Exome Sequencing , 2013, Human mutation.

[26]  Gunnar Houge,et al.  Monoallelic and biallelic mutations in MAB21L2 cause a spectrum of major eye malformations. , 2014, American journal of human genetics.

[27]  J. Reis-Filho,et al.  Epistatic interactions and drug response , 2014, The Journal of pathology.

[28]  Leslie G Biesecker,et al.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. , 2010, American journal of human genetics.

[29]  R. Rangel,et al.  A novel phenotype characterized by digital abnormalities, intellectual disability, and short stature in a Mexican family maps to Xp11.4–p11.21 , 2013, American journal of medical genetics. Part A.

[30]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[31]  E. Souied,et al.  Exome sequencing identifies mutations in LZTFL1, a BBSome and smoothened trafficking regulator, in a family with Bardet–Biedl syndrome with situs inversus and insertional polydactyly , 2012, Journal of Medical Genetics.

[32]  S. Fisher,et al.  Dissection of epistasis in oligogenic Bardet–Biedl syndrome , 2006, Nature.

[33]  M. Kalia,et al.  Biomarkers for personalized oncology: recent advances and future challenges. , 2015, Metabolism: clinical and experimental.

[34]  L. Wong,et al.  A novel EBP c.224T>A mutation supports the existence of a male‐specific disorder independent of CDPX2 , 2014, American journal of medical genetics. Part A.